Tofacitinib for Treatment of Rheumatoid Arthritis.

Tofacitinib for Treatment of Rheumatoid Arthritis.
Adv Ther. 2013 Aug 14;
Authors: Rakieh C, Conaghan PG
Abstract
The management of rheumatoid arthritis has seen a dramatic improvement with the introduction of a range of biological disease modifying anti-rheumatic drugs (DMARDs) in recent years. Nonetheless, a proportion of patients remain resistant or intolerant to multiple conventional and biological DMARDs, so innovative strategies are needed to offer patients new therapeutic options. Tofacitinib is the first of a new class of orally active DMARDs, with immunomodulating effects through inhibition of intracellular Janus kinase (JAK) pathways. It has been recently licensed for treatment of adults with moderate to severe RA in the US, Japan, and Russia. In this review the authors evaluate the efficacy and safety of tofacitinib in RA, focusing predominantly on the phase 3 study data.
PMID: 23943546 [PubMed - as supplied by publisher]

Source: Advances in Therapy - August 14, 2013 Category: Drugs & Pharmacology Authors: Rakieh C, Conaghan PG Tags: Adv Ther Source Type: research